BIOPIX DNA Technology P.C. receives EU funding

BIOPIX-T (www.biopix-t.com ) is pleased to announce that a consortium of eight partners in which it participated, has been awarded EU funding (€2.4M) under the emergency call H2020-SC1-PHE-CORONAVIRUS-2020-2. The aim of the proposal, entitled “Market Release of a Portable Device for COVID-19 at the Point-of-Care; a Global Diagnostics Approach” with the acronym “IRIS-COV”, is the immediate development, certification and release of BIOPIX-T ‘s novel diagnostic platform, IRIS, to carry out a combined test for SARS-CoV–2 and Influenza A.  

In addition to BIOPIX-T (medical device designer, manufacturer and provider), the consortium includes IMBB-FORTH who will coordinate the project, three hospitals in Europe (UCLH-UK, INSERM-France and ULB-Belgium) which will perform the clinical validations, one consulting company for the certification (PKNM-Switzerland), one enzyme-biotech SME (EnzyQuest-Greece) and an end-user in South Africa (Kiara Health). The “IRIS-COV” project is one of the 23 to receive funding from a total of 454 submitted proposals (https://ec.europa.eu/info/files/new-research-projects-coronavirus_en ). 

“This funding will allow BIOPIX-T to accelerate the certification of its products and enter the market in time to contribute meaningfully to the controlling of the COVID19 pandemic. Our low-cost device is designed for decentralized testing (point-of-need) and provides real-time quantitative results, which are comparable to the “gold standard”, lab-based devices. Its “connected” nature, as it is being operated through a smart device, makes it a perfect tool for monitoring of the disease spread. We look forward to releasing our product in the market as soon as possible and fulfilling our mission to offer portable devices for global diagnostics” said Dr. George Papadakis, co-founder and CEO of BIOPIX-T. 


BIOPIX DNA TECHNOLOGY P.C. (https://biopix-t.com) was founded in December 2019 in order to commercialize a novel molecular diagnostic method, developed by the founding team, for the detection of nucleic acids at the point-of-care.  

The company targets two healthcare-diagnostics related markets through the production of standardized assays for detection and monitoring of Infectious Diseases and Companion Diagnostics.  

BIOPIX-T operates out of the Science and Technology Park of Crete (STEP-C) and is in the process of becoming a certified Medical Devices Designer and Manufacturer.